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ABSTRACT
Background: The impact of dietary flavonoid intakes on risk of
depression is unclear.
Objective: We prospectively examined associations between es-
timated habitual intakes of dietary flavonoids and depression
risk.
Design: We followed 82,643 women without a previous history of
depression at baseline from the Nurses’ Health Study [(NHS) aged
53–80 y] and the Nurses’ Health Study II [(NHSII) aged 36–55 y].
Intakes of total flavonoids and subclasses (flavonols, flavones,
flavanones, anthocyanins, flavan-3-ols, polymeric flavonoids,
and proanthocyanidins) were calculated from validated food-
frequency questionnaires collected every 2–4 y. Depression
was defined as physician- or clinician-diagnosed depression or
antidepressant use and was self-reported in response to periodic
questionnaires. Cox proportional hazards models were performed
to examine associations.
Results: A total of 10,752 incident depression cases occurred dur-
ing a 10-y follow-up. Inverse associations between flavonol, fla-
vone, and flavanone intakes and depression risk were observed.
Pooled multivariable-adjusted HRs (95% CIs) were 0.93 (0.88,
0.99), 0.92 (0.86, 0.98), and 0.90 (0.85, 0.96) when comparing the
highest (quintile 5) with the lowest (quintile 1) quintiles, respec-
tively, with evidence of linear trends across quintiles (P-trend =
0.0004–0.08). In flavonoid-rich food-based analyses, the HR was
0.82 (95% CI: 0.74, 0.91) among participants who consumed $2
servings citrus fruit or juices/d compared with ,1 serving/wk. In
the NHS only, total flavonoids, polymers, and proanthocyanidin in-
takes showed significantly (9–12%) lower depression risks. In anal-
yses among late-life NHS participants (aged $65 y at baseline or
during follow-up), for whom we were able to incorporate depressive
symptoms into the outcome definition, higher intakes of all flavo-
noid subclasses except for flavan-3-ols were associated with sig-
nificantly lower depression risk; flavones and proanthocyanidins
showed the strongest associations (HR for both: 0.83; 95% CI:
0.77, 0.90).
Conclusions: Higher flavonoid intakes may be associated with
lower depression risk, particularly among older women. Further
studies are needed to confirm these associations. Am J Clin Nutr
2016;104:704–14.
Keywords: depression, epidemiology, flavonoids, geriatrics, Nurses’
Health Study, prospective cohort
INTRODUCTION
Depression is a major contributor to the global burden of
disease- and illness-related disability (1). Althoughmany patients
respond favorably to treatment, residual symptoms and dys-
function from depression are common, especially among older
adults (2). Therefore, effective prevention strategies are critical
for lowering the overall burden (3).
Dietary modification seems appealing for depression pre-
vention (4), yet the existing literature with regard to diet-
depression relations has often been hampered by key limitations,
including lack of prospective design and insufficient assessment
of exposure (5). Dietary flavonoids represent a diverse range of
polyphenolic compounds that occur naturally in plant foods, and
they are present in substantial amounts in commonly consumed
fruit, vegetables, grains, herbs, and beverages. The structural
complexity of flavonoids has led to their subclassification as
flavonols, flavones, flavanones, flavan-3-ols (and their oligomers,
proanthocyanidins), isoflavones, and anthocyanins. Flavonoid
compounds have been shown to exert antineuroinflammatory
properties (6) and to suppress neuronal apoptosis and stimulate
prosurvival signaling cascades (7)—mechanisms that may be
involved in depression pathophysiology. In addition, some fla-
vonoids appear to improve vascular health principally via en-
hanced blood flow (8, 9), which may be relevant to late-life
depression, in which vascular disease burden has been impli-
cated as a major factor (10). Moreover, higher habitual intakes
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of flavonoids/flavonoid-rich foods have already been associated
with lower risks of many health outcomes (11–17). However,
whether flavonoids present in the habitual diet are associated
with depression is unknown.
Therefore, in this study, we prospectively examined whether
self-reported long-term dietary intakes of flavonoid subclasses, as
well as specific flavonoid-rich foods, were related to lower de-
pression incidence, which was ascertained by self-report of
physician or clinician diagnosis of depression or antidepressant
use, in 2 large female cohorts: the Nurses’ Health Study (NHS)9
and the Nurses’ Health Study II (NHSII). We further investigated
the presence and magnitude of associations for flavonoids/
flavonoid-rich foods on depression risk among late-life partici-
pants (aged $65 y at baseline or during follow-up). We hypoth-
esized that higher intakes of flavonoids, particularly flavonones,
anthocyanins, and proanthocyanidins (17, 18), would be associated
with lower depression risk.
METHODS
The NHS and NHSII
The NHS began in 1976 when 121,700 US female nurses, aged
30–55 y, returned a mailed questionnaire on lifestyle and med-
ical history. In 1989, the NHSII began when a younger cohort of
116,430 women, aged 25–42 y, was enrolled via responding to
similar mailed questionnaires. Since the start of each cohort,
participants have received questionnaires biennially to update
medical outcomes and health and lifestyle factors.
Assessment of dietary flavonoid intake
A semiquantitative food-frequency questionnaire (FFQ) was
included in 1984 and 1986 and every 4 y thereafter in the NHS
and every 4 y since 1991 in the NHSII. On the FFQs, participants
were asked how often, on average, they consumed a standard
portion of w130 different foods in the previous year.
A database for assessing intakes of different flavonoid sub-
classes was constructed as described elsewhere (11). Briefly,
intakes of flavonoid-rich foods were converted into different
flavonoid subclasses, by multiplying the consumption frequency
of each food by its flavonoid content. Because flavonoid sub-
classes have structural variation and differ in both bioavailability
and bioactivity, we focused on the main subclasses commonly
consumed in the US diet: flavonols (quercetin, kaempferol,
myricetin, and isohamnetin), flavones (luteolin and apigenin),
flavanones (eriodictyol, hesperetin, and naringenin), flavan-3-ols
monomers (catechins, gallocatechins, epicatechins, epigallocatechin,
epicatechin-3-gallate, and epigallocatechin-3-gallate), anthocya-
nins (cyanidin, delphinidin, malvidin, pelargonin, petunidin, and
peonidin), and polymers (proanthocyanidins, theaflavins, and
thearubigins). We defined “total flavonoids” as the sum of these
subclasses. In addition, we examined proanthocyanidins sepa-
rately, summing monomers, dimers, trimers, 4- to 6-mers, 7- to
10-mers, and .10-mers, because of plausible specific benefits for
neuroprotection (18). We estimated energy-adjusted cumulative
average intakes to assess long-term flavonoid intake and to min-
imize within-person variation; intakes were categorized into
cohort-specific quintiles for analyses. For questionnaire cycles
without an FFQ, we used the cumulative average assessed through
the previous cycle. The validity and reproducibility of the FFQs
were previously reported: for example, correlations between sev-
eral major dietary sources of flavonoids including apples, tea, and
wine measured by weighted diet records and FFQs were 0.70,
0.77, and 0.83, respectively (19–21).
Assessment of depression
Depression assessments in the NHS/NHSII include self-report
of symptoms, medications, and diagnosis. Symptoms were first
assessed by using the 5-item Mental Health Index (MHI-5)
subscale of the Short-Form 36 Health Status Survey on the 1992,
1996, and 2000 questionnaires in the NHS and the 1993, 1997,
and 2001 questionnaires in the NHSII. In the NHS, symptoms
continued to be assessed by the following measures: the 10-item
version of the Center for Epidemiologic Studies Depression
(CESD-10) in 2004 and the 15-item version of the Geriatric
Depression Scale (GDS-15) in 2008. The MHI-5, CESD-10, and
GDS-15 all have published validated cutoffs for clinical de-
pression (22–25). Questions on regular antidepressant use were
assessed biennially since 1996 (NHS) or 1997 (NHSII). Finally,
participants were first asked if they ever had doctor-diagnosed
depression in 2000 (NHS) or 2001 (NHSII) and were assessed
biennially afterward. Because these were the first years in which
we could classify women as ever having physician- or clinician-
diagnosed depression, we designated 2000 and 2001 as the study
baselines for NHS and NHSII, respectively.
In both cohorts, incident depression was defined as the first
occurrence of self-reported clinical indicators of depression (i.e.,
doctor-diagnosed depression and/or regular antidepressant use),
as in previous work (26). For antidepressants, we included se-
lective serotonin reuptake inhibitors (SSRIs) but excluded
tricyclic antidepressants (TCAs), because evidence elsewhere
indicated that TCAswould bemore likely to be prescribed for other
indications (27). In both cohorts, history of depression at baseline
was determined by the following: 1) self-report of ever physician-
diagnosed depression, 2) self-reported use of SSRIs, and/or 3)
MHI-5 score of #52 before or at baseline questionnaires.
In a secondary analysis we examined associations between
flavonoid intakes and late-life depression risk (i.e., among women
aged$65 y at baseline or during follow-up in the NHS; no women
in the NHSII were in this age range during follow-up). Within this
NHS subset, we incorporated the presence of severe depressive
symptoms with the use of published cutoffs ($10 on the CESD-10
and $6 on the GDS-15) in the case definition.
Covariates
We selected sociodemographic, lifestyle, and health/medical
factors a priori on the basis of previous literature on depression
risk factors (28) and our own preliminary data on risk indicators
of depression. Sociodemographic factors included age, census-
tract median family income (a proxy of socioeconomic status),
9 Abbreviations used: aMed, alternate Mediterranean diet; CESD-10, 10-item
version of the Center for Epidemiologic Studies Depression; FFQ, food-
frequency questionnaire; GDS-15, 15-item version of the Geriatric Depres-
sion Scale; MHI-5, 5-item Mental Health Index; NHS, Nurses’ Health Study;
NHSII, Nurses’ Health Study II; SSRI, selective serotonin reuptake inhibitor;
TCA, tricyclic antidepressant.
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social network index (29), and subjective social status (10-point
visual analog scale of subjective feeling about standing in US
society). Lifestyle variables included cigarette smoking, BMI (in
kg/m2), alcohol intake, coffee consumption (30), physical activity
[determined by using a validated assessment from which metabolic
equivalents (metabolic equivalent-hours per week) could be
quantified] (31), and modified alternate Mediterranean diet (aMed)
adherence (32) (excluding fruit, vegetable, and alcohol compo-
nents to avoid overadjustment). Health/medical covariates included
bodily pain, sleep problems (sleep difficulty and sleep duration),
menopausal status, postmenopausal hormone use, multivitamin
use, and medical comorbidities. Covariates were updated every
2–4 y, as available. We carried forward the covariate information
in the previous questionnaire cycle if missing during follow-up.
Sample for analysis
After the exclusion of participants with a missing baseline
2000 or 2001 questionnaire, implausible daily energy intake
(,600 or .3500 kcal/d), missing information on previous his-
tory of depression, or no health examination anytime during
the follow-up (i.e., no opportunity for depression detection by
a clinician), 45,985 NHS and 36,658 NHSII women were in-
cluded for analysis (Supplemental Figure 1). The institutional
review board at Brigham and Women’s Hospital reviewed and
approved this study, and participants provided informed consent
by returning their questionnaires.
Statistical analysis
Individuals contributed person-years from the baseline ques-
tionnaire return date to the date of incident depression, death, end
of follow-up (NHS: June 2010; NHSII: June 2011), or last
returned questionnaire, whichever occurred first. We used time-
dependent Cox proportional hazards regressions to estimate the
age- and multivariable-adjusted RRs of depression, measured by
HRs with 95% CIs. Multivariable-adjusted models adjusted
for the following: age, census-tract median family income
(,$50,000, $50,000–69,999, or $$70,000/y), social network
(quintiles), subjective social status [bottom 4 steps of the social
ladder (i.e., lower status) or fifth step or above], cigarette
smoking (never; past; or current:1–14, 15–24, or$25 cigarettes/d),
BMI (continuous), alcohol intake (0, .0 to ,5, 5 to ,30, 30 to
,45, or $45 g/d), physical activity (continuous), coffee con-
sumption (#1 serving/wk, 2–6 servings/wk, 1 serving/d, 2–3
servings/d, or $4 servings/d), modified aMed score (quintiles),
total energy intake (kcal/d; continuous), current multivitamin use
(yes or no), menopausal status and postmenopausal hormone use
(premenopausal or postmenopausal; never, past, or current post-
menopausal hormone user), sleep hours (#6, 7–8, or $9 h/d),
frequency of difficulty falling or staying asleep (none, little, or
some to all of the time), bodily pain (none to mild or moderate to
very severe), and medical comorbidities (hypertension, cardio-
vascular disease, diabetes, and hypercholesterolemia; yes or no).
In primary analyses, we first characterized flavonoid intakes as
quintiles without assuming linear flavonoid-depression associa-
tions; we further tested for potential linear trends across flavonoid
quintiles by using a continuous variable in which participants
were assigned the median value of their quintile. We first con-
ducted analyses separately for each cohort and then conducted
meta-analyses by using random-effects models to obtain com-
bined estimates. Because the follow-up began in 2000 (NHS) or
2001 (NHSII), but the closest information of dietary flavonoids
was collected in 1998 (NHS) or 1999 (NHSII), the analyses
featured a 2-y outcome lag, which mitigated potential reverse
causation (e.g., incipient depression may lead to changes in diet).
To address concerns of exposure misclassification, outcome
misclassification, or competing risks, we performed 3 sensitivity
analyses. First, we stopped updating diet after a report of incident
cancer (except for nonmelanoma skin cancer), cardiovascular
disease, or diabetes, because individuals may substantially alter
their diet after diagnosis of a major disease; instead, the cumulative
averages of flavonoid intakes up to the most recent dietary data
before diagnosis of a major diseasewere carried forward thereafter.
Second, we applied alternative definitions of depression when
examining flavonoid-depression associations—including defini-
tions based on the presence of both diagnosis and antidepressant
use (more strict definition), diagnosis only, or diagnosis or anti-
depressant use including the use of TCAs (less strict definition).
Third, it is possible that individuals with severe chronic diseases
(cancer, cardiovascular disease, or diabetes) were less likely to
respond to the questionnaires; thus, we censored participants at
the time when they first reported these chronic conditions.
In secondary analyses, we conducted food-based analyses.
Specifically, we addressed foods that, on the basis of previous
published work elsewhere (11), are known to contribute to the
flavonoid subclasses that were associated with depression risk in
our primary analyses; we related intake amounts of those foods to
depression risk. In addition, we specifically investigated relations
of flavonoids to risk of depression in late life in 41,920 NHS
women aged $65 y at baseline or during follow-up.
All of the analyses were conducted with SAS version 9.3 (SAS
Institute). All P values were 2-sided (P , 0.05).
RESULTS
There were 10,752 cases (NHS: 4896; NHSII: 5856) of in-
cident depression cases identified during follow-up. At baseline,
participants with higher total flavonoid intakes had healthier
lifestyle behaviors (including higher levels of physical activity
and a lower prevalence of current smoking) and higher family
income (Table 1). The polymer and flavone subclasses con-
tributed most and least, respectively, to total flavonoid intakes
(IQR: 98.7–272.9 compared with 1.1–2.6 mg/d). NHS and NHSII
participants had high completion on exposure and outcome data
collection during follow-up (Supplemental Table 1). During the
10-y follow-up, each participant, on average, contributed 8.73
person-years. The number of exposure and outcome data collec-
tions and the average follow-up years per person did not vary by
quintiles of flavonoid intakes (data not shown).
Table 2 shows the associations between cumulative averages
of flavonoid intakes and depression risk in both cohorts. Ob-
served incidence rates of depression were 12.3 and 18.2 cases/
1000 person-years in the NHS and NHSII, respectively. In the
multivariable-adjusted pooled analyses of all participants, in-
dividuals in the highest (quintile 5) compared with the lowest
(quintile 1) quintile of flavonol, flavone, and flavanone intakes
had a significant 7–10% reduction in depression risk; there was
evidence of inverse linear trends across quintiles (P-trend = 0.08,
0.0004, and 0.0007, respectively) (Table 2). Results differed by
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cohort for other subclasses. Specifically, in the NHS, higher
intakes of total polymers and proanthocyanidins were signifi-
cantly associated with a lower risk of depression (P-trend = 0.04
and 0.03, respectively); yet, comparable results were not ob-
served in the NHSII. Furthermore, a greater intake of total fla-
vonoids was associated with significantly lower depression risk
only in the NHS, with evidence of effect heterogeneity in several
quintile groups between cohorts.
A sensitivity analysis, in which dietary information was no
longer updated after participants developed major chronic con-
ditions, yielded results similar to those in Table 2 (Supplemental
Table 2). Results were similar when different outcome definitions
TABLE 1
Age-standardized characteristics of the study population by quintiles of total flavonoid intake at baseline in the NHS (2000) and the NHSII (2001)1
Quintile of total flavonoid intake
NHS (2000) NHSII (2001)
1 3 5 1 3 5
n 9197 9197 9197 7331 7334 7332
Age, y 65.5 6 7.02 66.9 6 7.0 66.8 6 7.1 46.0 6 4.7 46.1 6 4.7 46.7 6 4.5
BMI, kg/m2 26.6 6 5.3 26.4 6 4.9 26.3 6 5.0 26.5 6 6.2 25.8 6 5.6 26.3 6 5.9
Census-tract median family income,
in 1000 US$
62.4 6 23.6 64.4 6 24.9 64.9 6 24.9 64.4 6 22.4 67.5 6 24.9 66.1 6 24.3
Total energy intake, kcal/d 1803.2 6 458.9 1781.7 6 436.2 1595.9 6 393.6 1755.8 6 467.7 1846.9 6 458.5 1762.2 6 462.4
Total flavonoids, mg/d 127.6 6 30.0 266.2 6 22.7 787.3 6 396.4 126.0 6 29.4 264.2 6 22.7 779.4 6 325.2
Flavonols, mg/d 9.9 6 3.9 15.0 6 4.1 28.3 6 9.4 10.4 6 4.8 15.9 6 5.4 31.4 6 11.3
Flavones, mg/d 1.4 6 0.7 2.3 6 0.9 2.2 6 1.2 1.2 6 0.8 2.0 6 1.0 1.9 6 1.1
Flavanones, mg/d 28.2 6 18.6 49.8 6 27.5 49.7 6 33.2 21.9 6 16.7 41.1 6 28.4 38.4 6 31.0
Flavan-3-ols, mg/d 12.3 6 5.4 31.1 6 11.0 137.1 6 72.0 11.8 6 5.2 29.7 6 10.1 146.1 6 75.7
Anthocyanins, mg/d 6.8 6 4.5 13.8 6 9.0 15.8 6 15.8 6.7 6 4.8 14.4 6 9.4 15.9 6 17.1
Polymeric flavonoids, mg/d 69.0 6 21.5 154.2 6 27.8 554.2 6 324.7 75.3 6 21.7 162.6 6 27.2 548.8 6 247.3
Proanthocyanidins, mg/d 65.9 6 21.3 117.1 6 33.5 169.5 6 61.0 70.1 6 22.1 123.7 6 36.4 179.9 6 65.0
Orange juice,3 servings/d 0.3 6 0.3 0.5 6 0.4 0.4 6 0.4 0.2 6 0.3 0.4 6 0.4 0.3 6 0.4
Oranges,3 servings/d 0.1 6 0.1 0.3 6 0.2 0.2 6 0.2 0.1 6 0.1 0.2 6 0.2 0.2 6 0.2
Grapefruit juice,3 servings/d 0.1 6 0.1 0.1 6 0.2 0.1 6 0.2 0.0 6 0.1 0.1 6 0.2 0.1 6 0.2
Grapefruit,3 servings/d 0.1 6 0.1 0.2 6 0.2 0.1 6 0.2 0.0 6 0.1 0.1 6 0.1 0.1 6 0.2
Apples or pears,3 servings/d 0.2 6 0.1 0.4 6 0.3 0.4 6 0.3 0.1 6 0.1 0.3 6 0.2 0.3 6 0.3
Tea,3 servings/d 0.1 6 0.1 0.3 6 0.3 1.8 6 1.1 0.0 6 0.1 0.2 6 0.2 1.9 6 1.0
Strawberries,3 servings/d 0.1 6 0.1 0.1 6 0.1 0.1 6 0.1 0.1 6 0.1 0.1 6 0.1 0.1 6 0.2
Blueberries,3 servings/d 0.0 6 0.0 0.1 6 0.1 0.1 6 0.1 0.0 6 0.0 0.1 6 0.1 0.1 6 0.1
Red wine,3 servings/d 0.0 6 0.1 0.1 6 0.2 0.1 6 0.2 0.0 6 0.1 0.1 6 0.2 0.1 6 0.2
Onions,3 servings/d 0.1 6 0.2 0.2 6 0.2 0.1 6 0.2 0.1 6 0.1 0.1 6 0.2 0.1 6 0.2
Coffee,3 servings/d 1.9 6 1.5 1.5 6 1.3 1.1 6 1.1 1.3 6 1.5 1.2 6 1.2 0.9 6 1.2
Alcohol, g/d 7.3 6 11.0 5.7 6 8.2 4.4 6 6.9 3.5 6 6.1 3.6 6 5.4 3.1 6 5.4
aMed score 3.6 6 1.4 4.6 6 1.4 4.1 6 1.4 3.3 6 1.5 4.6 6 1.6 4.2 6 1.6
Physical activity, MET-h/wk 14.8 6 18.8 19.9 6 22.9 18.2 6 21.5 17.7 6 21.4 23.8 6 27.5 22.2 6 25.5
Current smoker, % 13.3 5.0 6.4 9.8 4.7 6.2
Postmenopausal, % 98.9 98.9 98.7 30.2 30.1 32.3
Current hormone use,4 % 44.6 46.9 45.0 52.6 55.3 56.4
Low self-rated societal position
(bottom 4 of 10 ladders), %
2.0 1.3 1.3 1.7 1.4 1.9
High social network (top 2 quintiles), % 29.7 33.5 30.8 32.2 35.3 34.9
Normal sleep hours (7–8 h/d), % 65.7 67.7 66.1 68.8 70.7 67.2
Difficulty falling or staying asleep,
some to all of the time, %
32.5 30.3 29.7 23.8 23.5 23.5
Bodily pain, moderate or more, % 22.4 20.8 21.0 12.7 12.3 13.9
Current multivitamin use, % 63.9 69.6 67.5 53.2 61.5 59.7
Cancer, % 14.6 15.4 15.5 8.6 9.5 9.3
Hypertension, % 48.3 47.8 47.7 15.5 14.1 16.8
Hypercholesterolemia, % 60.2 60.1 60.7 28.8 26.4 27.5
Heart disease, % 8.0 6.5 7.9 1.1 0.9 0.8
Diabetes, % 8.2 7.4 7.9 2.2 2.1 2.1
1n = 82,643. All variables were age-adjusted except for age. aMed, alternate Mediterranean diet; MET-h, metabolic equivalent task hours; NHS, Nurses’
Health Study; NHSII, Nurses’ Health Study II.
2Mean 6 SD (all such values).
3One serving = 1 orange, one-half grapefruit, 1 small glass of orange juice, 1 small glass of grapefruit juice, 1 fresh apple or pear, 1 cup (240 mL) tea, 0.5
cup strawberries or blueberries, 0.5 cup onions, 4 oz (120 mL) glass red wine, or 1 cup caffeinated coffee.
4Among postmenopausal women only.
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TABLE 2
HRs (95% CIs) for associations between flavonoid subclass intakes and incident depression among women in the NHS and the NHSII1
Quintile of intake
P-trend1 2 3 4 5
Total flavonoids, mg/d
NHS #177.8 .177.8–238.9 .238.9–315.2 .315.2–462.5 .462.5
Cases/person-years, n/n 1089/79,907 963/79,893 955/79,785 959/79,792 930/79,913
Model 12 1.00 (referent) 0.89 (0.81, 0.97) 0.89 (0.82, 0.97) 0.89 (0.81, 0.97) 0.85 (0.78, 0.93) 0.01
Model 23 1.00 (referent) 0.91 (0.83, 1.00) 0.92 (0.84, 1.01) 0.91 (0.83, 1.00) 0.88 (0.80, 0.97) 0.04
NHSII #182.4 .182.4–247.0 .247.0–326.4 .326.4–478.7 .478.7
Cases/person-years, n/n 1262/64,567 1236/64,393 1103/64,304 1096/64,361 1159/64,351
Model 12 1.00 (referent) 1.03 (0.95, 1.11) 0.95 (0.87, 1.03) 0.95 (0.87, 1.03) 0.98 (0.91, 1.06) 0.45
Model 23 1.00 (referent) 1.03 (0.95, 1.11) 0.95 (0.88, 1.03) 0.96 (0.88, 1.04) 1.00 (0.92, 1.09) 0.91
Meta-analyzed results
Random-effects model4 1.00 (referent) 0.97 (0.86, 1.09) 0.94 (0.88, 1.00) 0.94 (0.88, 1.00) 0.94 (0.84, 1.07) 0.30
P-heterogeneity 0.05 0.62 0.44 0.04 0.13
Flavonols, mg/d
NHS #10.8 .10.8–13.8 .13.8–17.2 .17.2–22.5 .22.5
Cases/person-years, n/n 1011/79,951 1044/79,876 995/79,773 949/79,803 897/79,888
Model 12 1.00 (referent) 1.05 (0.96, 1.15) 1.01 (0.93, 1.11) 0.97 (0.88, 1.06) 0.91 (0.83, 0.99) 0.003
Model 23 1.00 (referent) 1.06 (0.97, 1.15) 1.03 (0.94, 1.12) 0.99 (0.90, 1.09) 0.93 (0.85, 1.02) 0.02
NHSII #11.3 .11.3–14.7 .14.7–18.7 .18.7–25.0 .25.0
Cases/person-years, n/n 1253/64,658 1165/64,452 1139/64,441 1183/64,162 1116/64,263
Model 12 1.00 (referent) 0.98 (0.90, 1.06) 0.98 (0.90, 1.06) 1.04 (0.95, 1.12) 0.98 (0.90, 1.06) 0.96
Model 23 1.00 (referent) 0.95 (0.87, 1.03) 0.93 (0.85, 1.01) 0.98 (0.90, 1.07) 0.94 (0.86, 1.02) 0.37
Meta-analyzed results
Random-effects model4 1.00 (referent) 1.00 (0.90, 1.11) 0.97 (0.88, 1.07) 0.99 (0.93, 1.05) 0.93 (0.88, 0.99) 0.08
P-heterogeneity 0.07 0.12 0.91 0.90 0.22
Flavones, mg/d
NHS #1.3 .1.3–1.8 .1.8–2.3 .2.3–3.0 .3.0
Cases/person-years, n/n 1030/79,857 1003/79,992 1014/79,844 915/79,876 934/79,721
Model 12 1.00 (referent) 0.98 (0.90, 1.07) 0.99 (0.90, 1.08) 0.90 (0.82, 0.98) 0.91 (0.83, 0.99) 0.01
Model 23 1.00 (referent) 0.99 (0.91, 1.09) 1.01 (0.92, 1.11) 0.92 (0.84, 1.01) 0.94 (0.86, 1.03) 0.07
NHSII #1.1 .1.1–1.5 .1.5–2.0 .2.0–2.6 .2.6
Cases/person-years, n/n 1261/64,547 1286/64,418 1206/64,318 1090/64,366 1013/64,328
Model 12 1.00 (referent) 1.05 (0.98, 1.14) 1.02 (0.94, 1.11) 0.92 (0.85, 1.00) 0.88 (0.81, 0.96) ,0.0001
Model 23 1.00 (referent) 1.04 (0.96, 1.13) 1.01 (0.93, 1.09) 0.93 (0.85, 1.01) 0.90 (0.83, 0.99) 0.001
Meta-analyzed results
Random-effects model4 1.00 (referent) 1.02 (0.96, 1.08) 1.01 (0.95, 1.07) 0.92 (0.87, 0.98) 0.92 (0.86, 0.98) 0.0004
P-heterogeneity 0.46 0.94 0.84 0.53 0.34
Flavanones, mg/d
NHS #20.2 .20.2–33.2 .33.2–46.5 .46.5–64.2 .64.2
Cases/person-years, n/n 1037/79,801 971/79,877 984/79,845 956/79,914 948/79,854
Model 12 1.00 (referent) 0.93 (0.85, 1.02) 0.94 (0.86, 1.02) 0.90 (0.82, 0.98) 0.86 (0.79, 0.94) 0.001
Model 23 1.00 (referent) 0.95 (0.87, 1.04) 0.97 (0.89, 1.06) 0.94 (0.85, 1.02) 0.91 (0.82, 0.99) 0.04
NHSII #14.0 .14.0–22.8 .22.8–33.9 .33.9–51.5 .51.5
Cases/person-years, n/n 1235/64,295 1225/64,266 1206/64,295 1126/64,463 1064/64,657
Model 12 1.00 (referent) 1.00 (0.92, 1.08) 0.98 (0.91, 1.07) 0.91 (0.84, 0.99) 0.84 (0.77, 0.91) ,0.0001
Model 23 1.00 (referent) 1.00 (0.92, 1.08) 0.99 (0.92, 1.08) 0.95 (0.87, 1.03) 0.90 (0.83, 0.98) 0.006
Meta-analyzed results
Random-effects model4 1.00 (referent) 0.98 (0.92, 1.04) 0.98 (0.92, 1.04) 0.94 (0.89, 1.00) 0.90 (0.85, 0.96) 0.0007
P-heterogeneity 0.46 0.78 0.85 0.97 0.60
Flavan-3-ols, mg/d
NHS #15.7 .15.7–24.8 .24.8–39.7 .39.7–72.1 .72.1
Cases/person-years, n/n 1062/79,920 981/79,817 963/79,778 925/79,871 965/79,905
Model 12 1.00 (referent) 0.94 (0.86, 1.03) 0.94 (0.86, 1.03) 0.89 (0.81, 0.97) 0.92 (0.84, 1.01) 0.12
Model 23 1.00 (referent) 0.96 (0.88, 1.05) 0.96 (0.88, 1.05) 0.91 (0.83, 0.99) 0.94 (0.86, 1.03) 0.18
NHSII #16.0 .16.0–25.2 .25.2–39.9 .39.9–74.9 .74.9
Cases/person-years, n/n 1220/64,631 1164/64,339 1132/64,278 1154/64,298 1186/64,431
Model 12 1.00 (referent) 1.01 (0.93, 1.09) 1.01 (0.93, 1.10) 1.02 (0.94, 1.11) 1.02 (0.95, 1.11) 0.56
Model 23 1.00 (referent) 0.99 (0.91, 1.07) 0.97 (0.89, 1.05) 0.99 (0.91, 1.08) 1.00 (0.93, 1.09) 0.66
(Continued)
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were applied, but the 95% CIs were wider when the more strict
definition was used—likely due to the reduced numbers of cases
(Supplemental Table 3). We conducted a competing risk anal-
ysis, in which participants were censored when a major disease
(cancer, heart disease, or diabetes) occurred; this reduced person-
years by 29% and 16% in the NHS and NHSII, respectively.
However, findings from the competing risk analysis were similar
to those from the primary analyses (Supplemental Table 4).
Finally, given the potential for confounding by other nutrients in
flavonoid-rich foods that may be associated with depression, we
TABLE 2 (Continued )
Quintile of intake
P-trend1 2 3 4 5
Meta-analyzed results
Random-effects model4 1.00 (referent) 0.97 (0.92, 1.04) 0.97 (0.91, 1.03) 0.95 (0.87, 1.00) 0.97 (0.91, 1.04) 0.64
P-heterogeneity 0.72 0.93 0.15 0.27 0.19
Anthocyanins, mg/d
NHS #5.9 .5.9–9.3 .9.3–13.4 .13.4–20.1 .20.1
Cases/person-years, n/n 1099/79,947 983/79,946 942/79,821 910/79,880 962/79,696
Model 12 1.00 (referent) 0.91 (0.83, 0.99) 0.89 (0.81, 0.97) 0.87 (0.79, 0.95) 0.94 (0.86, 1.03) 0.38
Model 23 1.00 (referent) 0.92 (0.85, 1.01) 0.92 (0.84, 1.00) 0.91 (0.83, 1.00) 1.00 (0.91, 1.10) 0.52
NHSII #6.3 .6.3–10.5 .10.5–15.3 .15.3–23.2 .23.2
Cases/person-years, n/n 1331/64,672 1253/64,563 1154/64,355 1105/64,292 1013/64,095
Model 12 1.00 (referent) 1.00 (0.92, 1.08) 0.95 (0.88, 1.03) 0.95 (0.87, 1.02) 0.92 (0.84, 1.00) 0.02
Model 23 1.00 (referent) 1.01 (0.93, 1.09) 0.97 (0.89, 1.05) 0.97 (0.89, 1.05) 0.95 (0.87, 1.04) 0.17
Meta-analyzed results
Random-effects model4 1.00 (referent) 0.97 (0.89, 1.06) 0.94 (0.89, 1.00) 0.94 (0.88, 1.00) 0.97 (0.91, 1.04) 0.70
P-heterogeneity 0.14 0.38 0.33 0.41 0.17
Polymeric flavonoids, mg/d
NHS #96.3 .96.3–137.2 .137.2–190.9 .190.9–300.6 .300.6
Cases/person-years, n/n 1072/79,925 998/79,856 952/79,809 937/79,806 937/79,895
Model 12 1.00 (referent) 0.95 (0.87, 1.04) 0.92 (0.84, 1.00) 0.89 (0.82, 0.98) 0.89 (0.81, 0.97) 0.01
Model 23 1.00 (referent) 0.98 (0.90, 1.07) 0.95 (0.87, 1.04) 0.93 (0.85, 1.02) 0.91 (0.83, 1.00) 0.04
NHSII #108.6 .108.6–151.9 .151.9–208.0 .208.0–321.9 .321.9
Cases/person-years, n/n 1270/64,623 1181/64,379 1120/64,276 1124/64,321 1161/64,378
Model 12 1.00 (referent) 0.98 (0.90, 1.06) 0.96 (0.89, 1.05) 0.97 (0.89, 1.05) 0.98 (0.90, 1.06) 0.76
Model 23 1.00 (referent) 0.97 (0.90, 1.05) 0.96 (0.89, 1.05) 0.97 (0.90, 1.06) 0.99 (0.91, 1.07) 0.91
Meta-analyzed results
Random-effects model4 1.00 (referent) 0.98 (0.92, 1.04) 0.96 (0.90, 1.02) 0.95 (0.90, 1.01) 0.96 (0.88, 1.03) 0.39
P-heterogeneity 0.86 0.88 0.46 0.19 0.10
Proanthocyanidins, mg/d
NHS #79.9 .79.9–103.3 .103.3–127.3 .127.3–160.0 .160.0
Cases/person-years, n/n 1108/79,935 975/79,907 1002/79,877 929/79,775 882/79,796
Model 12 1.00 (referent) 0.89 (0.82, 0.98) 0.93 (0.85, 1.01) 0.87 (0.80, 0.95) 0.82 (0.75, 0.90) ,0.0001
Model 23 1.00 (referent) 0.92 (0.84, 1.00) 0.96 (0.88, 1.05) 0.92 (0.84, 1.01) 0.89 (0.81, 0.97) 0.03
NHSII #87.7 .87.7–114.0 .114.0–141.5 .141.5–179.0 .179.0
Cases/person-years, n/n 1298/64,671 1237/64,498 1170/64,384 1109/64,234 1042/64,189
Model 12 1.00 (referent) 1.00 (0.92, 1.08) 0.98 (0.91, 1.06) 0.95 (0.88, 1.03) 0.93 (0.86, 1.01) 0.05
Model 23 1.00 (referent) 1.00 (0.93, 1.09) 0.99 (0.91, 1.07) 0.98 (0.90, 1.06) 0.97 (0.89, 1.06) 0.40
Meta-analyzed results
Random-effects model4 1.00 (referent) 0.96 (0.88, 1.05) 0.97 (0.92, 1.03) 0.95 (0.89, 1.01) 0.93 (0.85, 1.02) 0.08
P-heterogeneity 0.13 0.61 0.39 0.17 0.24
1n = 82,643. HRs (95% CIs) for depression by intake category of total flavonoids and individual subclasses of flavonoids were analyzed by using Cox
proportional hazards models. The test for trend was performed by using the median value for each intake category. Depression was assessed by either self-
reported physician diagnosis or regular use of antidepressant medication. NHS, Nurses’ Health Study; NHSII, Nurses’ Health Study II.
2Model 1 adjusted for age and questionnaire cycle.
3Model 2 adjusted for age, questionnaire cycle, total energy intake (continuous), social network (quintiles), alternate Mediterranean diet score (quintiles;
excluding components of vegetables, fruit, and alcohol), census-tract family income (,$50,000, $50,000–69,999, or $$70,000/y), alcohol intake (0, 0.1–4.9,
5.0–29.9, 30–44.9, or $45.0 g/d), subjective self-rated societal position (low or other), cigarette smoking (never; past; current: 1–14, 15–24, or$25 cigarettes/d),
BMI (continuous), physical activity in total metabolic equivalents per week (continuous), actual sleep hours (#6, 7–8, or $9 h/d), frequency of difficulty
falling or staying asleep (none, little, or some to all of the time), bodily pain (none to mild or moderate to very severe), current multivitamin use (yes
or no), coffee consumption (#1 serving/wk, 2–6 servings/wk, 1 serving/d, 2–3 servings/d, or $4 servings/d), menopausal status and postmenopausal
hormone use [premenopausal or postmenopausal (never postmenopausal hormone user, past postmenopausal hormone user, or current postmenopausal
hormone user)], history of hypertension (yes or no), history of cardiovascular disease (yes or no), history of diabetes (yes or no), and history of
hypercholesterolemia (yes or no).
4Data were meta-analyzed by using random-effects model of results from model 2.
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performed additional analyses that further adjusted for intakes of
omega-3 fatty acids, vitamin C, vitamin B-6, vitamin B-12, and
folate; the results were unchanged (data not shown). The results
remained the same when the aMed score adjusted for in the model
also included fruit and vegetable components (data not shown).
We then conducted food-based analyses for the major sources of
the flavonoid subclasses that were significantly associated with
lower depression risk in the pooled results in Table 2: flavonols,
flavones, and flavanones. The predominant flavone and flavanone
contributors, citrus (including orange and grapefruit) fruit and juices
(33), were significantly inversely associated with depression risk
in a dose-response fashion. Compared with citrus intake of ,1
serving/wk, intakes of $2 servings/d were associated with an 18%
reduction in depression risk (Table 3); this association was con-
sistent in both cohorts. Both citrus fruit and juices were in-
dividually associated with lower depression risk (P-trend = 0.001
and 0.05, respectively); however, although moderate consumption
of citrus fruit was related to lower depression risk, the significant
association between citrus juice and lower depression risk was seen
only at the highest consumption amount. With regard to flavonols,
tea and onions are 2 major contributors. Being in the highest ($4
cups/d) compared with the lowest (rarely or never) tea consumption
group was significantly associated with a 12% lower risk of de-
pression; onion intake was not associated with depression risk.
In the analyses of flavonoids and late-life depression (i.e., women
aged$65 y at baseline or during follow-up) (Supplemental Table
5), the observed incidence rate was 12.0 cases/1000 person-years
when depression was defined by self-report of physician or clini-
cian diagnosis or antidepressant treatment. When the outcome in-
cluded diagnosis, antidepressant use, and/or clinically relevant
depressive symptoms, the incidence rate was 24.2 cases/1000 person-
years, which is consistent with sex-specific late-life incidence rates of
any depression (i.e., either minor or major depression) observed
elsewhere (34, 35). Importantly, comparing results by using the
different definitions of depression, the patterns of inverse associa-
tions between dietary flavonoids and late-life depression were
consistent. However, effect estimates appeared stronger, with nar-
rower 95% CIs, in analyses that incorporated depressive symptoms.
For example, placement in quintile 5 (compared with quintile 1) for
almost all flavonoid subclasses was related to significantly lower
depression risk, with evidence of linear trends. The exception was
flavan-3-ols monomers (Table 4), which suggests that polymers of
flavan-3-ols may be more relevant than monomers to late-life de-
pression risk. The strongest associations were seen for flavones and
proanthocyanidins (quintile 5 compared with quintile 1; HR for
both: 0.83; 95% CI: 0.77, 0.90). The complementary food-based
analysis showed that higher intakes of apples/pears and citrus were
associated with lower depression risk (P-trend = 0.002 and 0.02,
respectively) (Table 5).
DISCUSSION
To our knowledge, this is the first large-scale prospective study
to examine the association between self-reported habitual intakes
of major flavonoid subclasses and depression risk. Combining via
meta-analysis the results from the NHS and NHSII cohorts,
which were composed of middle-aged (i.e., NHSII: mean age of
46 y at baseline) and older (i.e., NHS: mean age of 67 y at
baseline) women, we observed that the highest intakes of fla-
vonols, flavones, and flavanones were significantly associated
with a 7–10% lower risk of depression compared with the lowest
intakes; higher intakes of flavan-3-ols and anthocyanins were
not significantly associated with lower depression risk. In ad-
dition, total flavonoids, polymeric flavonoids, and proantho-
cyanidins were associated only with a significant reduction in
depression risk in the older cohort of participants (i.e., NHS) but
not among the middle-aged women of the NHSII.
Although the association estimates were moderate and in-
tervention trials are needed to further understand the clinical
TABLE 3
Pooled HRs (95% CIs) for associations between intakes of flavonoid-rich food and incident depression among women in the NHS and the NHSII1
Intake category2
P-trend1 2 3 4 5
Citrus fruit and juice results 1.00 (referent) 0.94 (0.85, 1.05) 0.89 (0.78, 1.02) 0.85 (0.75, 0.97) 0.82 (0.74, 0.91) ,0.0001
Citrus fruit 1.00 (referent) 0.93 (0.88, 0.99) 0.91 (0.86, 0.96) 0.97 (0.83, 1.13) 0.87 (0.75, 1.01) 0.001
Citrus juice 1.00 (referent) 0.99 (0.88, 1.12) 0.98 (0.92, 1.05) 0.96 (0.88, 1.04) 0.90 (0.82, 0.98) 0.05
Tea 1.00 (referent) 0.96 (0.90, 1.02) 0.98 (0.92, 1.04) 0.96 (0.90, 1.03) 0.88 (0.78, 1.00) 0.30
Onions 1.00 (referent) 1.00 (0.94, 1.06) 0.98 (0.92, 1.05) 0.96 (0.89, 1.02) 0.99 (0.89, 1.09) 0.25
1n = 82,643. Depression was assessed by either self-reported physician diagnosis or regular use of antidepressant medication. HRs (95% CIs) for
depression by intake category of total flavonoids and individual subclasses of flavonoids were analyzed by using Cox proportional hazards models. The test for
trend was performed by using the median value for each intake category. Model adjusted for age, questionnaire cycle, total energy intake (continuous), social
network (quintiles), alternate Mediterranean diet score (quintiles), census-tract family income (,$50,000, $50,000–69,999, or $$70,000/y), alcohol intake
(0, 0.1–4.9, 5.0–29.9, 30–44.9, or $45.0 g/d), subjective self-rated societal position (low or other), cigarette smoking (never; past; current: 1–14, 15–24, or
$25 cigarettes/d), BMI (continuous), physical activity in total metabolic equivalents per week (continuous), actual sleep hours (#6, 7–8, or $9 h/d),
frequency of difficulty falling or staying asleep (none, little, or some to all of the time), bodily pain (none to mild or moderate to very severe), current
multivitamin use (yes or no), coffee consumption (#1 serving/wk, 2–6 servings/wk, 1 serving/d, 2–3 servings/d, or $4 servings/d), menopausal status and
postmenopausal hormone use [premenopausal or postmenopausal (never postmenopausal hormone user, past postmenopausal hormone user, or current
postmenopausal hormone user)], history of hypertension (yes or no), history of cardiovascular disease (yes or no), history of diabetes (yes or no), and history
of hypercholesterolemia (yes or no). Data were meta-analyzed using random-effects models. NHS, Nurses’ Health Study; NHSII, Nurses’ Health Study II.
2Category values were as follows—citrus fruit and juice, citrus fruit, and citrus juice: 1 (,1 serving/wk), 2 (1 serving/wk), 3 (2–6 servings/wk),
4 (1 serving/d), and 5 ($2 servings/d); tea: 1 (,1 serving/mo), 2 ($1 serving/mo to #1 serving/wk), 3 (2–6 servings/wk), 4 (1–3 servings/d), and
5 ($4 servings/d); onion: 1 (,1 serving/mo), 2 (1–3 servings/mo), 3 (1 serving/wk), 4 (2–4 servings/wk), and 5 ($5 servings/wk). One serving = 1 orange,
one-half grapefruit, 1 small glass of orange juice, 1 small glass of grapefruit juice, 1 cup (240 mL) tea, or 0.5 cup onions.
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importance of these findings, several points can be highlighted.
First, despite modest effect estimates, at a population level the
results may be important. By using a population-attributable risk
framework, 5% of the depression cases that occurred in both the
NHS and NHSII could have been prevented if all women in the
lowest 3 quintiles of flavanone intakes switched to the highest 2
quintile of intakes. Importantly, such computations require as-
sumptions of causal links, which can only be established in
randomized trials or other experimental approaches; thus,
population-attributable risk estimates are more speculative in
observational studies. Nevertheless, they are helpful at conveying
the broader concept that small effect estimates from a common
exposure can translate to relatively larger impacts on health.
Second, although the magnitudes of overall estimates of asso-
ciation were modest in the primary analysis, the associations
were stronger with respect to late-life depression. For example,
women in the highest quintile of flavones and proanthocyanidins
showed a significant 17% reduction in the risk of late-life depression.
Third, the significant dose-response relation and consistency
across 2 cohorts for several specific flavonoids made the observed
inverse associations less likely to be due to chance.
Available evidence with regard to flavonoid-depression as-
sociations is limited, particularly data from epidemiologic studies
and trials. Existing work has focused on intakes of a specific
flavonoid-rich food (typically, cocoa or tea) or overall fruit and
vegetable consumption. Inverse associations were observed in
some studies, but most were cross-sectional and did not involve
comprehensive evaluations of flavonoid subclasses or a broad
range of food sources (36–38). Moreover, our results are in line
with evidence of favorable relations of flavonoids to other later-
life brain outcomes, including cognitive decline and Parkinson
disease (13, 17). Finally, preliminary evidence from randomized
controlled trials suggested benefits of specific flavonoid com-
pounds for reducing depressive symptoms or enhancing mood
(39, 40). However, most of these randomized controlled trials
focused on short-term action of flavonoids on change in de-
pressive symptoms and had small sample sizes. Overall, there is
no comparable evidence with regard to whether long-term habitual
intakes of flavonoids affect depression risk. Thus, the current
study makes a unique contribution to the literature.
Although the specific links between flavonoids and depression
are unclear, growing evidence supports a beneficial role for
TABLE 4
HRs (95% CIs) for associations between flavonoid subclass intakes and incident late-life depression among women in the NHS, aged $65 y1
Quintile of intake
P-trend1 2 3 4 5
Late-life depression, assessed by
self-reported diagnosis, treatment,
or severe symptoms2
Total flavonoids 1.00 (referent) 0.96 (0.89, 1.03) 0.96 (0.89, 1.04) 0.92 (0.85, 0.99) 0.89 (0.82, 0.96) 0.003
Flavonols 1.00 (referent) 1.05 (0.97, 1.13) 0.98 (0.91, 1.06) 0.91 (0.84, 0.99) 0.90 (0.83, 0.97) 0.0001
Flavones 1.00 (referent) 0.96 (0.89, 1.04) 0.95 (0.88, 1.02) 0.91 (0.84, 0.98) 0.83 (0.77, 0.90) ,0.0001
Flavanones 1.00 (referent) 0.91 (0.84, 0.98) 0.96 (0.88, 1.03) 0.93 (0.86, 1.00) 0.86 (0.80, 0.93) 0.001
Flavan-3-ols 1.00 (referent) 0.97 (0.90, 1.05) 0.95 (0.88, 1.02) 0.90 (0.83, 0.97) 0.93 (0.86, 1.01) 0.07
Anthocyanins 1.00 (referent) 0.90 (0.84, 0.97) 0.92 (0.85, 0.99) 0.86 (0.79, 0.93) 0.90 (0.83, 0.97) 0.03
Polymeric flavonoids 1.00 (referent) 1.00 (0.92, 1.07) 0.96 (0.89, 1.03) 0.94 (0.87, 1.02) 0.88 (0.82, 0.96) 0.0007
Proanthocyanidins 1.00 (referent) 0.95 (0.88, 1.02) 0.96 (0.89, 1.03) 0.92 (0.85, 1.00) 0.83 (0.77, 0.90) ,0.0001
Late-life depression, assessed by
self-reported diagnosis or treatment3
Total flavonoids 1.00 (referent) 0.90 (0.81, 1.00) 0.91 (0.81, 1.01) 0.91 (0.82, 1.01) 0.87 (0.78, 0.97) 0.05
Flavonols 1.00 (referent) 1.10 (0.99, 1.21) 0.97 (0.87, 1.08) 0.96 (0.86, 1.07) 0.93 (0.84, 1.04) 0.03
Flavones 1.00 (referent) 1.04 (0.94, 1.16) 1.07 (0.96, 1.19) 0.99 (0.89, 1.11) 0.94 (0.84, 1.05) 0.14
Flavanones 1.00 (referent) 0.98 (0.88, 1.09) 1.02 (0.92, 1.14) 0.96 (0.86, 1.07) 0.91 (0.82, 1.02) 0.08
Flavan-3-ols 1.00 (referent) 0.95 (0.86, 1.05) 0.95 (0.86, 1.06) 0.87 (0.78, 0.97) 0.91 (0.82, 1.02) 0.11
Anthocyanins 1.00 (referent) 0.93 (0.84, 1.04) 0.96 (0.86, 1.06) 0.96 (0.86, 1.07) 1.04 (0.93, 1.16) 0.22
Polymeric flavonoids 1.00 (referent) 0.99 (0.89, 1.10) 0.96 (0.86, 1.07) 0.93 (0.84, 1.04) 0.88 (0.79, 0.99) 0.01
Proanthocyanidins 1.00 (referent) 0.92 (0.83, 1.03) 0.99 (0.89, 1.10) 0.96 (0.87, 1.07) 0.88 (0.78, 0.98) 0.05
1n = 41,920. HRs (95% CIs) for depression by intake category of total flavonoids and individual subclasses of flavonoids were analyzed by using Cox
proportional hazards models. The test for trend was performed by using the median value for each intake category. Model adjusted for age, questionnaire
cycle, total energy intake (continuous), social network (quintiles), alternate Mediterranean diet score (quintiles; excluding components of vegetables, fruit,
and alcohol), census-tract family income (,$50,000, $50,000–69,999, or $$70,000/y), alcohol intake (0, 0.1–4.9, 5.0–29.9, 30–44.9, or $45.0 g/d),
subjective self-rated societal position (low or other), cigarette smoking (never; past; current: 1–14, 15–24, or $25 cigarettes/d), BMI (continuous), physical
activity in total metabolic equivalents per week (continuous), actual sleep hours (#6, 7–8, or $9 h/d), frequency of difficulty falling or staying asleep
(none, little, or some to all of the time), bodily pain (none to mild or moderate to very severe), current multivitamin use (yes or no), coffee consumption (#1
serving/wk, 2–6 servings/wk, 1 serving/d, 2–3 servings/d, or $4 servings/d), menopausal status and postmenopausal hormone use [premenopausal or
postmenopausal (never postmenopausal hormone user, past postmenopausal hormone user, or current postmenopausal hormone user)], history of hypertension
(yes or no), history of cardiovascular disease (yes or no), history of diabetes (yes or no), and history of hypercholesterolemia (yes or no). NHS, Nurses’ Health
Study.
2Late-life depression assessed by either self-reported physician diagnosis, regular use of antidepressant medication, or the presence of severe depressive
symptoms. The incident rate was 6734 cases/278,582.4 = 24.2 cases/1000 person-years.
3Late-life depression assessed by either self-reported physician diagnosis or regular use of antidepressant medication. The incident rate was 3527 cases/294,800 =
12.0 cases/1000 person-years.
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flavonoids on mood and brain health (41, 42), and direct and
indirect mechanisms have been suggested (43). Direct mecha-
nisms may include modulating signaling pathways responsible
for maintaining neuron survival and inducing synaptic plasticity
(7, 42, 44). Indirect mechanisms may include reducing neuro-
inflammation, improving blood flow, or reducing oxidative stress
(6, 8, 9, 45). However, it is unclear whether the different flavonoid
subclasses and their metabolites share generic neuroprotection
properties or whether particular flavonoids are more neuro-
protective than others. It is important to note that, although many
flavonoid metabolites are shown to cross the blood-brain barrier
(46, 47), the beneficial effects of specific flavonoids may depend
on their bioavailability—influenced by absorption, metabolism, and
disposition in tissues and cells—which differs greatly by subclasses
(48, 49). For example, flavanones are more efficiently absorbed
than most other subclasses and have longer elimination half-lives
(50). Among the older cohort (i.e., NHS), polymers including
proanthocyanidins were also associated with lower depression risk.
Although the full range of biological mechanisms of flavonoids
involved in depression remains to be elucidated, proanthocyanidin-
rich botanical extracts have been shown to prevent depressive-like
behaviors in proneurotoxin-treated rats and to promote anti-
inflammatory and antioxidant activities in rats (51, 52).
Strengths of this study include the following: a large sample
size; its prospective design; a comprehensive assessment of the
full range of flavonoid subclasses in habitual diet; long-term,
detailed, and repeated measures of flavonoids and covariates; and
lengthy follow-up. Limitations also warrant discussion. For
example, it is impossible to include every single food and nutrient
in the FFQ, and flavonoid values calculated from the most recent
databases (11) could be misclassified because flavonoid contents
of foods vary by growth and processing conditions (53) and
analytic extraction methods (54). In addition, some foods with
different flavonoid contents are grouped together into single
questions (e.g., apples and pears are grouped together, and black
and green teas are not differentiated in the NHS/NHSII FFQs).
Therefore, some degree of exposure misclassification is likely.
However, the quartile ranking is less likely to be affected by such
misclassification, and fruit and vegetable intakes assessed from
an FFQ and weighted diet records correlated well in repro-
ducibility and validity studies in the NHS and NHSII cohorts
(19–21). Although we did not have objective biomarkers of
flavonoid intakes, such as urinary metabolite excretion, mea-
sured in this study, good correlations between flavonoid biomarker
concentrations and fruit/vegetable intakes (0.43–0.66) have been
reported elsewhere (55). Potential misclassification of the de-
pression outcome must also be considered, despite past success
in using this definition to show important disease associations
(26). For example, some degree of underascertainment of de-
pression in this study is likely, because participants’ physicians
or clinicians may not detect depression when it is present, cli-
nicians may not inform participants of the depression diagnosis,
or participants may elect not to report on the questionnaires the
depression diagnoses they received or their antidepressant use
information. However, the rates we observed are consistent with
previously reported rates for major depression in women (34,
35). The rate observed for the broader depression definition in
older women (diagnosis, treatment, and/or symptoms) is almost
identical to that reported elsewhere when depression is similarly
defined (34, 35). The use of the more conservative, clinical
indicators-only outcome definition may bias results toward the
null; therefore, our primary analysis results may be underestimates.
In addition, SSRIs are prescribed not only for depression but also
for other psychiatric conditions; this may generate false-positive
TABLE 5
HRs (95% CIs) for associations between intakes of flavonoid-rich food and incident late-life depression among women aged $65 y in the NHS1
Intake category2
P-trend1 2 3 4 5
Citrus fruit and juices 1.00 (referent) 0.90 (0.75, 1.09) 0.88 (0.76, 1.01) 0.90 (0.77, 1.05) 0.84 (0.72, 0.97) 0.02
Tea 1.00 (referent) 1.02 (0.94, 1.11) 0.96 (0.89, 1.04) 0.98 (0.90, 1.07) 0.88 (0.75, 1.04) 0.11
Onions 1.00 (referent) 0.98 (0.89, 1.06) 1.01 (0.92, 1.10) 0.96 (0.88, 1.05) 0.93 (0.82, 1.04) 0.22
Apples or pears 1.00 (referent) 0.99 (0.83, 1.18) 0.91 (0.76, 1.09) 0.92 (0.77, 1.09) 0.84 (0.71, 1.01) 0.002
Strawberries 1.00 (referent) 0.99 (0.87, 1.12) 0.97 (0.85, 1.09) 0.95 (0.84, 1.08) 0.92 (0.73, 1.14) 0.22
Blueberries 1.00 (referent) 0.96 (0.90, 1.02) 0.95 (0.88, 1.02) 0.97 (0.88, 1.08) 0.70 (0.46, 1.07) 0.17
Red wine 1.00 (referent) 1.03 (0.96, 1.10) 0.98 (0.90, 1.08) 0.91 (0.83, 1.01) 0.94 (0.81, 1.08) 0.09
1n = 41,920. HRs (95% CIs) for depression by intake category of total flavonoids and individual subclasses of flavonoids were analyzed by using Cox
proportional hazards models. The test for trend was performed by using the median value for each intake category. Model adjusted for age, questionnaire
cycle, total energy intake (continuous), social network (quintiles), alternate Mediterranean diet score (quintiles), census-tract family income (,$50,000,
$50,000–69,999, or $$70,000/y), alcohol intake (0, 0.1–4.9, 5.0–29.9, 30–44.9, or $45.0 g/d), subjective self-rated societal position (low or other), cigarette
smoking (never; past; current: 1–14, 15–24, or $25 cigarettes/d), BMI (continuous), physical activity in total metabolic equivalents per week (continuous),
actual sleep hours (#6, 7–8, or $9 h/d), frequency of difficulty falling or staying asleep (none, little, or some to all of the time), bodily pain (none to mild or
moderate to very severe), current multivitamin use (yes or no), coffee consumption (#1 serving/wk, 2–6 servings/wk, 1 serving/d, 2–3 servings/d, or$4 servings/d),
menopausal status and postmenopausal hormone use [premenopausal or postmenopausal (never postmenopausal hormone user, past postmenopausal hormone user,
or current postmenopausal hormone user)], history of hypertension (yes or no), history of cardiovascular disease (yes or no), history of diabetes (yes or no), and
history of hypercholesterolemia (yes or no). Late-life depression was assessed by either self-reported physician diagnosis, regular use of antidepressant medication,
or the presence of severe depressive symptoms. NHS, Nurses’ Health Study.
2Category values were as follows—citrus fruit and juices: 1 (,1 serving/wk), 2 (1 serving/wk), 3 (2–4 servings/wk), 4 (5–6 servings/wk), and 5 ($1
serving/d); tea: 1 (,1 serving/mo), 2 ($1 serving/mo to #1 serving/wk), 3 (2–6 servings/wk), 4 (1–3 servings/d), and 5 ($4 servings/d); onion, apples or
pears, strawberries, blueberries, and red wine: 1 (,1 serving/mo), 2 (1–3 servings/mo), 3 (1 serving/wk), 4 (2–4 servings/wk), and 5 ($5 servings/wk). One
serving = 1 orange, one-half grapefruit, 1 small glass of orange juice, 1 small glass of grapefruit juice, 1 fresh apple or pear, 1 cup (240 mL) tea, 0.5 cup
onions, 0.5 cup strawberries or blueberries, or one 4-ounce (120-mL) glass red wine.
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depression cases. Some true depression cases may also have been
missed because regular use of TCAs (,3% in both the NHS and
NHSII) was not included in the outcome definition. However, the
probability of correctly classifying individuals as cases is likely to
be independent of flavonoid intake and thus should not bias the
observed associations. Indeed, the results from the sensitivity
analyses applying more or less strict definitions showed similar
findings.
Other potential methodologic limitations should be discussed.
First, despite careful adjustment for potential confounders, residual
confounding is possible. Nevertheless, the detailed, updated ad-
justment for covariates render residual confounding unlikely to
account fully for the findings. We also cannot rule out that other
dietary components in fruit and vegetables may affect the results.
However, further adjustment for omega-3 fatty acid and vitamin C,
B-6, and B-12 or folate intakes did not attenuate the associations;
in addition, the results remained the samewhenwe adjusted for the
aMed score in the model (which includes fruit and vegetable
components). Second, our results could be biased if the censoring
mechanism was dependent on the mechanism that produced the
outcome of interest. However, follow-up was w90% in each 2-y
cycle in both cohorts and the competing risks analysis showed
similar results, suggesting that selection attrition was not a major
concern. Finally, our findings from this all-female, predominantly
white cohort may not be directly generalizable to men or to other
race/ethnic groups. Further research to observe directly the re-
lations between men and diverse race/ethnic groups would be
valuable.
In these large prospective female cohorts with 10 y of follow-
up, greater intakes of dietary flavonoids were significantly as-
sociated with a modest reduction in depression risk, particularly
among older women. Associations varied by different flavonoid
subclasses, pinpointing the importance of future studies to
confirm comparable findings in other cohorts and to clarify the
biological mechanisms whereby different flavonoid subclasses
may contribute to depression prevention. Further prospective
studies and intervention trials are needed to confirm these as-
sociations. If confirmed, the findings may have important im-
plications for depression prevention, because there are limited,
readily-modifiable risk factors for depression.
The authors’ responsibilities were as follows—S-CC and OIO: designed and
conducted the research, drafted the manuscript, and had primary responsibility
for final content; S-CC: analyzed data; AC, WCW, EBR, EJO: revised the
manuscript critically for important intellectual content; and all authors: read
and approved the final manuscript. None of the authors declared support from
any organization for the submitted work, financial relationships with any orga-
nization that might have an interest in the submitted work in the previous 3 y, or
other relationships or activities that could appear to have influenced the sub-
mitted work. EBR and AC have separate unassociated funding jointly with the
University of East Anglia to conduct observational and experimental studies of
blueberries and cardiovascular health outcomes from the USDA/US Blueberry
Highbush Council, outside the submitted work.
REFERENCES
1. Murray CJ, Lopez AD. Alternative projections of mortality and dis-
ability by cause 1990-2020: Global Burden of Disease Study. Lancet
1997;349:1498–504.
2. Beekman AT, Geerlings SW, Deeg DJ, Smit JH, Schoevers RS, de
Beurs E, Braam AW, Penninx BW, van Tilburg W. The natural history
of late-life depression: a 6-year prospective study in the community.
Arch Gen Psychiatry 2002;59:605–11.
3. Reynolds CF III, Cuijpers P, Patel V, Cohen A, Dias A, Chowdhary N,
Okereke OI, Dew MA, Anderson SJ, Mazumdar S, et al. Early in-
tervention to reduce the global health and economic burden of major
depression in older adults. Annu Rev Public Health 2012;33:123–35.
4. Stahl ST, Albert SM, Dew MA, Lockovich MH, Reynolds CF III.
Coaching in healthy dietary practices in at-risk older adults: a case of
indicated depression prevention. Am J Psychiatry 2014;171:499–505.
5. Sanhueza C, Ryan L, Foxcroft DR. Diet and the risk of unipolar de-
pression in adults: systematic review of cohort studies. J Hum Nutr
Diet 2013;26(1):56–70.
6. Vafeiadou K, Vauzour D, Lee HY, Rodriguez-Mateos A, Williams RJ,
Spencer JP. The citrus flavanone naringenin inhibits inflammatory
signalling in glial cells and protects against neuroinflammatory injury.
Arch Biochem Biophys 2009;484:100–9.
7. Spencer JP. Flavonoids and brain health: multiple effects underpinned
by common mechanisms. Genes Nutr 2009;4:243–50.
8. Morand C, Dubray C, Milenkovic D, Lioger D, Martin JF, Scalbert A,
Mazur A. Hesperidin contributes to the vascular protective effects of
orange juice: a randomized crossover study in healthy volunteers. Am J
Clin Nutr 2011;93:73–80.
9. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA,
Ryder JJ, Hall WL, Cassidy A. Flavonoids, flavonoid-rich foods, and
cardiovascular risk: a meta-analysis of randomized controlled trials.
Am J Clin Nutr 2008;88:38–50.
10. Santos M, Kovari E, Hof PR, Gold G, Bouras C, Giannakopoulos P.
The impact of vascular burden on late-life depression. Brain Res Rev
2009;62:19–32.
11. Cassidy A, O’Reilly EJ, Kay C, Sampson L, Franz M, Forman JP,
Curhan G, Rimm EB. Habitual intake of flavonoid subclasses and in-
cident hypertension in adults. Am J Clin Nutr 2011;93:338–47.
12. Cutler GJ, Nettleton JA, Ross JA, Harnack LJ, Jacobs DR Jr., Scrafford
CG, Barraj LM, Mink PJ, Robien K. Dietary flavonoid intake and risk
of cancer in postmenopausal women: the Iowa Women’s Health Study.
Int J Cancer 2008;123(3):664–71.
13. Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Ha-
bitual intake of dietary flavonoids and risk of Parkinson disease.
Neurology 2012;78:1138–45.
14. Letenneur L, Proust-Lima C, Le Gouge A, Dartigues JF, Barberger-
Gateau P. Flavonoid intake and cognitive decline over a 10-year period.
Am J Epidemiol 2007;165:1364–71.
15. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT.
Flavonoid intake and cardiovascular disease mortality in a prospective
cohort of US adults. Am J Clin Nutr 2012;95:454–64.
16. Wedick NM, Pan A, Cassidy A, Rimm EB, Sampson L, Rosner B, Willett
W, Hu FB, Sun Q, van Dam RM. Dietary flavonoid intakes and risk of
type 2 diabetes in US men and women. Am J Clin Nutr 2012;95:925–33.
17. Devore EE, Kang JH, Breteler MM, Grodstein F. Dietary intakes of
berries and flavonoids in relation to cognitive decline. Ann Neurol
2012;72:135–43.
18. Xu Y, Li S, Chen R, Li G, Barish PA, You W, Chen L, Lin M, Ku B,
Pan J, et al. Antidepressant-like effect of low molecular proanthocyanidin
in mice: involvement of monoaminergic system. Pharmacol Biochem
Behav 2010;94:447–53.
19. Salvini S, Hunter DJ, Sampson L, Stampfer MJ, Colditz GA, Rosner B,
Willett WC. Food-based validation of a dietary questionnaire: the ef-
fects of week-to-week variation in food consumption. Int J Epidemiol
1989;18:858–67.
20. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J,
Hennekens CH, Speizer FE. Reproducibility and validity of a semi-
quantitative food frequency questionnaire. Am J Epidemiol 1985;122:
51–65.
21. Willett W. Reproducibility and validity of food-frequency question-
naires. In: Nutritional epidemiology. 3rd ed. Oxford (United King-
dom): Oxford University Press; 2013. p. 96–141.
22. Berwick DM, Murphy JM, Goldman PA, Ware JE Jr., Barsky AJ,
Weinstein MC. Performance of a five-item mental health screening test.
Med Care 1991;29:169–76.
23. Yamazaki S, Fukuhara S, Green J. Usefulness of five-item and three-
item Mental Health Inventories to screen for depressive symptoms in
the general population of Japan. Health Qual Life Outcomes 2005;3:48.
24. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for
depression in well older adults: evaluation of a short form of the CES-D
(Center for Epidemiologic Studies Depression Scale). Am J Prev Med
1994;10:77–84.
DIETARY FLAVONOIDS AND DEPRESSION 713
25. Friedman B, Heisel MJ, Delavan RL. Psychometric properties of the
15-item Geriatric Depression Scale in functionally impaired, cogni-
tively intact, community-dwelling elderly primary care patients. J Am
Geriatr Soc 2005;53:1570–6.
26. Pan A, Sun Q, Czernichow S, Kivimaki M, Okereke OI, Lucas M,
Manson JE, Ascherio A, Hu FB. Bidirectional association between
depression and obesity in middle-aged and older women. Int J Obes
(Lond) 2012;36:595–602.
27. Okereke OI, Cook NR, Albert CM, Van Denburgh M, Buring JE,
Manson JE. Effect of long-term supplementation with folic acid and
B-vitamins on risk of depression in older women. Br J Psychiatry 2015;
206:324–31.
28. Schoevers RA, Smit F, Deeg DJ, Cuijpers P, Dekker J, van Tilburg W,
Beekman AT. Prevention of late-life depression in primary care: do we
know where to begin? Am J Psychiatry 2006;163:1611–21.
29. Berkman LF, Syme SL. Social networks, host resistance, and mortality:
a nine-year follow-up study of Alameda County residents. Am J Epi-
demiol 1979;109:186–204.
30. Lucas M, Mirzaei F, Pan A, Okereke OI, Willett WC, O’Reilly EJ,
Koenen K, Ascherio A. Coffee, caffeine, and risk of depression among
women. Arch Intern Med 2011;171:1571–8.
31. Wolf AM, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Corsano
KA, Rosner B, Kriska A, Willett WC. Reproducibility and validity of
a self-administered physical activity questionnaire. Int J Epidemiol
1994;23:991–9.
32. Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu
FB. Mediterranean diet and incidence of and mortality from coronary
heart disease and stroke in women. Circulation 2009;119:1093–100.
33. Cassidy A, Rimm EB, O’Reilly EJ, Logroscino G, Kay C, Chiuve SE,
Rexrode KM. Dietary flavonoids and risk of stroke in women. Stroke
2012;43:946–51.
34. Luijendijk HJ, van den Berg JF, Dekker MJ, van Tuijl HR, Otte W,
Smit F, Hofman A, Stricker BH, Tiemeier H. Incidence and recurrence
of late-life depression. Arch Gen Psychiatry 2008;65:1394–401.
35. Norton MC, Skoog I, Toone L, Corcoran C, Tschanz JT, Lisota RD,
Hart AD, Zandi PP, Breitner JC, Welsh-Bohmer KA, et al. Three-year
incidence of first-onset depressive syndrome in a population sample of
older adults: the Cache County study. Am J Geriatr Psychiatry 2006;14
(3):237–45.
36. Niu K, Hozawa A, Kuriyama S, Ebihara S, Guo H, Nakaya N, Ohmori-
Matsuda K, Takahashi H, Masamune Y, Asada M, et al. Green tea
consumption is associated with depressive symptoms in the elderly.
Am J Clin Nutr 2009;90:1615–22.
37. Mihrshahi S, Dobson AJ, Mishra GD. Fruit and vegetable consumption
and prevalence and incidence of depressive symptoms in mid-age
women: results from the Australian longitudinal study on women’s
health. Eur J Clin Nutr 2015;69:585–91.
38. Rose N, Koperski S, Golomb BA. Mood food: chocolate and de-
pressive symptoms in a cross-sectional analysis. Arch Intern Med
2010;170:699–703.
39. Sathyapalan T, Beckett S, Rigby AS, Mellor DD, Atkin SL. High cocoa
polyphenol rich chocolate may reduce the burden of the symptoms in
chronic fatigue syndrome. Nutr J 2010;9:55.
40. Pase MP, Scholey AB, Pipingas A, Kras M, Nolidin K, Gibbs A,
Wesnes K, Stough C. Cocoa polyphenols enhance positive mood states
but not cognitive performance: a randomized, placebo-controlled trial.
J Psychopharmacol 2013;27:451–8.
41. Dias GP, Cavegn N, Nix A, do Nascimento Bevilaqua MC, Stangl D,
Zainuddin MS, Nardi AE, Gardino PF, Thuret S. The role of dietary
polyphenols on adult hippocampal neurogenesis: molecular mecha-
nisms and behavioural effects on depression and anxiety. Oxid Med
Cell Longev 2012;2012:541971.
42. Williams CM, El Mohsen MA, Vauzour D, Rendeiro C, Butler LT, Ellis
JA, Whiteman M, Spencer JP. Blueberry-induced changes in spatial
working memory correlate with changes in hippocampal CREB
phosphorylation and brain-derived neurotrophic factor (BDNF) levels.
Free Radic Biol Med 2008;45:295–305.
43. Rendeiro C, Rhodes JS, Spencer JP. The mechanisms of action of
flavonoids in the brain: direct versus indirect effects. Neurochem Int
2015;89:126–39.
44. Spencer JP, Rice-Evans C, Williams RJ. Modulation of pro-survival
Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and
its in vivo metabolites underlie their action on neuronal viability. J Biol
Chem 2003;278:34783–93.
45. Zhao Z, Wang W, Guo H, Zhou D. Antidepressant-like effect of
liquiritin from Glycyrrhiza uralensis in chronic variable stress induced
depression model rats. Behav Brain Res 2008;194:108–13.
46. Milbury PE, Kalt W. Xenobiotic metabolism and berry flavonoid
transport across the blood-brain barrier. J Agric Food Chem 2010;58:
3950–6.
47. Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-
Evans C. Interaction between flavonoids and the blood-brain barrier: in
vitro studies. J Neurochem 2003;85:180–92.
48. Scalbert A, Morand C, Manach C, Remesy C. Absorption and me-
tabolism of polyphenols in the gut and impact on health. Biomed
Pharmacother 2002;56:276–82.
49. Manach C, Donovan JL. Pharmacokinetics and metabolism of dietary
flavonoids in humans. Free Radic Res 2004;38:771–85.
50. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bio-
availability and bioefficacy of polyphenols in humans. I. Review of 97
bioavailability studies. Am J Clin Nutr 2005;81(1 Suppl):230S–42S.
51. Nardi GM, Siqueira JM Jr., Delle Monache F, Pizzolatti MG, Ckless K,
Ribeiro-do-Valle RM. Antioxidant and anti-inflammatory effects of
products from Croton celtidifolius Bailon on carrageenan-induced
pleurisy in rats. Phytomedicine 2007;14:115–22.
52. Moreira EL, Rial D, Aguiar AS Jr., Figueiredo CP, Siqueira JM,
DalBo S, Horst H, de Oliveira J, Mancini G, dos Santos TS, et al.
Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers
neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine rat model of Parkinson’s disease. J Neural Transm (Vienna)
2010;117:1337–51.
53. Harnly JM, Doherty RF, Beecher GR, Holden JM, Haytowitz DB,
Bhagwat S, Gebhardt S. Flavonoid content of U.S. fruits, vegetables,
and nuts. J Agric Food Chem 2006;54:9966–77.
54. Drossard C, Frohling B, Dietrich H, Kersting M. Anthocyanin analysis
in banana fruit—a mistake. Am J Clin Nutr 2011;93:865–6; author
reply: 6–7.
55. Krogholm KS, Bysted A, Brantsaeter AL, Jakobsen J, Rasmussen SE,
Kristoffersen L, Toft U. Evaluation of flavonoids and enterolactone in
overnight urine as intake biomarkers of fruits, vegetables and beverages
in the Inter99 cohort study using the method of triads. Br J Nutr 2012;
108:1904–12.
714 CHANG ET AL.
